Skip to content

Efficacy and safety of focused low-intensity pulsed ultrasound therapy versus pulsed short-wave diathermy for the management of knee osteoarthritis: a randomized, single-blind, controlled trial

Efficacy and safety of focused low-intensity pulsed ultrasound therapy versus pulsed short-wave diathermy for the management of knee osteoarthritis: a randomized, single-blind, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032735
Enrollment
Unknown
Registered
2020-05-08
Start date
2020-05-31
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Experimental group:focused low-intensity pulsed ultrasound therapy
control group:pulsed SWD therapy

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. In line with the KOA diagnostic standard established by ARA. 2. Aged >= 40 years, male or female; 3. Knee OA fulfilling the ACR classification criteria, Kellgren & Lawrence class rating of II, and III; 4. Those who are willing to participant in this trial and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Rheumatoid arthritis, gouty arthritis, infectious arthritis or other joint diseases; 2. Patients with local skin ulceration, skin infection, severe surgical or traumatic scar, local malignant tumor of knee joint or joint replacement; 3. Patients with joint pain and dysfunction caused by other causes; 4. Patients with active peptic ulcer and bleeding, severe renal and liver dysfunction or bleeding tendency of coagulation dysfunction; 5. Patients with serious organic heart disease, such as myocardial infarction, heart failure, serious arrhythmia, pacemaker implantation or hypertension without treatment or drug control; 6. Patients with severe neurological or mental diseases who cannot cooperate with doctors; 7. Patients with systemic collagen connective tissue diseases, such as systemic lupus erythematosus, etc.; 8. Patients unable to understand the questionnaire; 9. Current or past (within 6 months) oral or intra-articular corticosteroid use; 10. A history of taking NSAIDs or symptomatic slow-acting drugs for OA (diacerein, hyaluronic acid) within the previous 2 weeks.

Design outcomes

Primary

MeasureTime frame
WOMAC;

Secondary

MeasureTime frame
VAS;Global rating of change score;Timed up and go test;Range of motion;

Countries

China

Contacts

Public ContactLang Jia

The Second Affiliated Hospital of Chongqing Medical University

93348047@qq.com+86 13677690535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026